GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » ProSomnus Inc (OTCPK:OSAPQ) » Definitions » EBITDA Margin %

ProSomnus (ProSomnus) EBITDA Margin % : 69.27% (As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is ProSomnus EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. ProSomnus's EBITDA for the three months ended in Mar. 2024 was $5.17 Mil. ProSomnus's Revenue for the three months ended in Mar. 2024 was $7.46 Mil. Therefore, ProSomnus's EBITDA margin for the quarter that ended in Mar. 2024 was 69.27%.


ProSomnus EBITDA Margin % Historical Data

The historical data trend for ProSomnus's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ProSomnus EBITDA Margin % Chart

ProSomnus Annual Data
Trend Dec20 Dec21 Dec22 Dec23
EBITDA Margin %
-43.15 -13.53 -3.10 -64.14

ProSomnus Quarterly Data
Dec20 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -90.17 30.93 -121.11 -68.74 69.27

Competitive Comparison of ProSomnus's EBITDA Margin %

For the Medical Devices subindustry, ProSomnus's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ProSomnus's EBITDA Margin % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, ProSomnus's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where ProSomnus's EBITDA Margin % falls into.



ProSomnus EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

ProSomnus's EBITDA Margin % for the fiscal year that ended in Dec. 2023 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-17.735/27.652
=-64.14 %

ProSomnus's EBITDA Margin % for the quarter that ended in Mar. 2024 is calculated as

EBITDA Margin %=EBITDA (Q: Mar. 2024 )/Revenue (Q: Mar. 2024 )
=5.166/7.458
=69.27 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ProSomnus  (OTCPK:OSAPQ) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


ProSomnus EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of ProSomnus's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


ProSomnus (ProSomnus) Business Description

Traded in Other Exchanges
N/A
Address
5675 Gibraltar Drive, Pleasanton, CA, USA, 94588
ProSomnus Inc is a medical device manufacturer. It manufacturers precision, mass-customized oral appliance therapy devices to treat obstructive sleep apnea, which affects over 74 million Americans and is associated with serious comorbidities, including heart failure, stroke, hypertension, morbid obesity and type 2 diabetes. ProSomnus's patented devices are more comfortable and less invasive alternative to continuous positive airway pressure therapy, and lead to more effective and patient-preferred outcomes.
Executives
Sung Kim officer: Chief Technical Officer 5675 GIBRALTAR AVENUE, PLEASANTON CA 94588
John Steffens 10 percent owner C/O DIGITALBRIDGE GROUP, INC., 750 PARK OF COMMERCE DRIVE SUITE 210, BOCCA RATON FL 33487
Gregory P. Ho 10 percent owner C/O SPRING MOUNTAIN CAPITAL, LP, 650 MADISON AVENUE, 20TH FLOOR, NEW YORK NY 10022
Brian B Dow officer: Chief Financial Officer 5675 GIBRALTAR AVENUE, PLEASANTON CA 94588
Smc Holdings Ii, Lp 10 percent owner 65 EAST 55TH STREET, 33RD FLOOR, NEW YORK NY 10022
Smc Holdings Ii G.p., Llc 10 percent owner C/O SPRING MOUNTAIN CAPITAL, LP, 650 MADISON AVENUE, 20TH FLOOR, NEW YORK NY 10022
Laing Rikkers director 5675 GIBRALTAR AVENUE, PLEASANTON CA 94588
Len Liptak director, officer: Chief Executive Officer 5675 GIBRALTAR AVENUE, PLEASANTON CA 94588
Mark Thomas Murphy officer: Chief Growth Officer 5675 GIBRALTAR AVENUE, PLEASANTON CA 94588
Hgp Iii, Llc 10 percent owner 3708 ASHFORD PLACE, GREENVILLE NC 27858
Steven Robert Pacelli director 5555 OBERLIN DRIVE, SAN DIEGO CA 92121
Hmc, Llc 10 percent owner 3708 ASHFORD PLACE, GREENVILLE NC 27858
Healthpointcapital, Llc 10 percent owner C/O HEALTHPOINTCAPITAL, 505 PARK AVENUE, 12TH FLOOR, NEW YORK NY 10022
Healthpointcapital Partners Iii Lp 10 percent owner 505 Park Avenue, 12th Floor, New York NY 10022
Leonard Hedge director 7855 BELLA MONTANIA LANE, PALO CEDRO CA 96073